Susquehanna International Group
ARDS

Susquehanna International Group’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Susquehanna International Group’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-69,500
Closed -$162K – 14322
2021
Q4 		$162K Buy
+69,500
New +$198K ﹤0.01% 11712

Other funds holding ARDS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group's ARDS Position: Q2 2023 in Review

Susquehanna International Group sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2023, closing a stake of 23,082 shares — an estimated $7.25K sold.

Susquehanna International Group first reported a position in ARDS in Q4 2021 and held it in 3 quarters. The position peaked at $127K in Q4 2021. 18 funds tracked by Wall St. Rank hold ARDS as of Q2 2023.

  • Susquehanna International Group reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 23,082 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2023, an estimated $7.25K.
  • Susquehanna International Group first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Susquehanna International Group's Aridis Pharmaceuticals Inc. Common Stock position peaked at $127K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.